Category: cancer vaccine

  • Nykode vaccine shows its worth in cervical cancer trial

    Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The combination of vaccine and checkpoint inhibitor had an overall response rate of 21% in the phase 2 VB C-02 trial involving 39 patients with HPV16-positive cervical cancer, including two complete […]

  • Imugene HER2 vaccine hits target in stomach cancer trial

    A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The interim readout from the 39-patient HERIZON trial found 50% of patients treated with the HER-Vaxx (IMU-131) vaccine on top of chemotherapy achieved a partial response […]

  • Roche pays $200m for Vaccibody’s cancer vaccine drug

    Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. The deal with the Oslo-based company is worth up to $715 million, with potential milestone payments worth up to $515 million on top […]

  • Regeneron pairs with BioNTech on melanoma immunotherapy

    Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors. The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech’s mRNA cancer immunotherapy BNT111, which is designed to stimulate immune […]